February's 10 biggest stories: Cardiac MRI | Late-breaking clinical trials | A key FDA approval | New CDC guidance

News You Need to Know Today

Monday, February 28, 2022

The Month in Review

Cardiac MRI sheds new light on vaccine-related myocarditis

Vaccine-associated myocarditis shows an injury pattern on cardiac MRI similar to other causes of myocarditis, but abnormalities are less severe.

COVID-19 vaccine associated myocarditis on short-axis 1.5T MRI images of a 19-year-old man who presented with chest pain three days following the second dose of an mRNA COVID-19 vaccine.

Cardiac MRI sheds new light on vaccine-related myocarditis

Vaccine-associated myocarditis shows an injury pattern on cardiac MRI similar to other causes of myocarditis, but abnormalities are less severe.

Heart drug trimetazidine at center of Olympics controversy surrounding figure skater Kamila Valieva

Trimetazidine, typically prescribed for treating angina, is associated with increasing blood flow and improving endurance.

Heart drug trimetazidine at center of Olympics controversy surrounding figure skater Kamila Valieva

Trimetazidine, typically prescribed for treating angina, is associated with increasing blood flow and improving endurance.

First implant of dual-chamber leadless pacemaker completed in Abbott’s Aveir DR i2i pivotal trial

The investigational dual-chamber pacemaker is designed to provide synchronous, beat-by-beat pacing of the right atrium and right ventricle of the heart.

The Abbott Aveir DR dual-chamber leadless pacemaker recently had its first human implant occur in the Aveir DR i2i study pivotal trial.

First implant of dual-chamber leadless pacemaker completed in Abbott’s Aveir DR i2i pivotal trial

The investigational dual-chamber pacemaker is designed to provide synchronous, beat-by-beat pacing of the right atrium and right ventricle of the heart.

Links to the ACC.22 late-breaking clinical trials

Learn more about the late-breaking studies presented at ACC.22 in Washington, D.C.

Links to the ACC.22 late-breaking clinical trials

Learn more about the late-breaking studies presented at ACC.22 in Washington, D.C.

Long-term risk of heart attack, coronary artery disease or stroke much higher among COVID-19 patients

Even patients who were never hospitalized for COVID-19 face a heightened risk of cardiovascular issues.

Long-term risk of heart attack, coronary artery disease or stroke much higher among COVID-19 patients

Even patients who were never hospitalized for COVID-19 face a heightened risk of cardiovascular issues.

4 new medications and technologies that could transform cardiology in 2022

The FDA has already approved one of the medications, with a decision on another expected by the end of April.

The LDL-lowering medication inclisiran (Leqvio) was recently cleared by the FDA. It used only two doses per year. It was included it the Cleveland Clinic annual list of the top 10 medical innovations expected to make a big impact on patient care in 2022.

4 new medications and technologies that could transform cardiology in 2022

The FDA has already approved one of the medications, with a decision on another expected by the end of April.

FDA approves empagliflozin for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

The SGLT2 inhibitor, already approved for some high-risk heart failure patients, has now received a much wider approval.

FDA approves empagliflozin for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

The SGLT2 inhibitor, already approved for some high-risk heart failure patients, has now received a much wider approval.

Hospital pays $3.8M to resolve allegations it assisted cardiologist in exchange for patient referrals

The New Hampshire hospital allegedly received referrals worth "millions of dollars."

Hospital pays $3.8M to resolve allegations it assisted cardiologist in exchange for patient referrals

The New Hampshire hospital allegedly received referrals worth "millions of dollars."

New CDC guidance: Waiting longer between COVID-19 vaccine doses could reduce risk of heart damage

Waiting a few additional weeks, the agency wrote, could help limit myocarditis or pericarditis among young adults.

Myocarditis as seen on cardiac MRI in patients who recently received COVID-19 messenger RNA vaccination from a November 2021 imaging study. Image courtesy of the American Journal of Roentgenology (AJR)

New CDC guidance: Waiting longer between COVID-19 vaccine doses could reduce risk of heart damage

Waiting a few additional weeks, the agency wrote, could help limit myocarditis or pericarditis among young adults.

Cardiologist dies after small plane crash in Minnesota

The 61-year-old cardiologist was piloting the plane when it crashed.

Cardiologist dies after small plane crash in Minnesota

The 61-year-old cardiologist was piloting the plane when it crashed.

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us | Unsubscribe from all | Privacy Policy

© Innovate Healthcare, a TriMed Media brand

The Month in Review

Recent Newsletters